Based on the NovaBay Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for NovaBay Pharmaceuticals Inc is USD 0.85 over the next 12 months. NovaBay Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of NovaBay Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, NovaBay Pharmaceuticals Inc’s stock price was USD 0.60. NovaBay Pharmaceuticals Inc’s stock price has changed by -0.83% over the past week, -7.69% over the past month and -87.82% over the last year.
No recent analyst target price found for NovaBay Pharmaceuticals Inc
No recent average analyst rating found for NovaBay Pharmaceuticals Inc
Company Overview NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Read Less
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova...Read More
Frequently Asked Questions About NovaBay Pharmaceuticals Inc (NBY) Stock
Based on ratings from 1 analysts NovaBay Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on NBY's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for NBY is USD 0.85 over the next 12 months. The maximum analyst target price is USD 0.85 while the minimum anlayst target price is USD 0.85.
NBY stock's Price/Earning ratio is 5.17.
Our analysis grades NBY stock's Price / Earning ratio at D-. This means that NBY stock's Price/Earning ratio is above 40% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this NBY may be fairly valued for its sector
The last closing price of NBY's stock was USD 0.60.
The most recent market capitalization for NBY is USD 3.18M.
Based on targets from 1 analysts, the average taret price for NBY is projected at USD 0.85 over the next 12 months.
This means that NBY's stock price may go up by +41.67% over the next 12 months.
We can't find any ETFs which contains NovaBay Pharmaceuticals Inc's stock.
As per our most recent records NovaBay Pharmaceuticals Inc has 24 Employees.
NovaBay Pharmaceuticals Inc's registered address is 2000 Powell Street, EmeryVille, CA, United States, 94608.
You can get more information about it from NovaBay Pharmaceuticals Inc's website at https://novabay.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About NovaBay Pharmaceuticals Inc (NBY) Stock
Based on ratings from 1 analysts NovaBay Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on NBY's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for NBY is USD 0.85 over the next 12 months. The maximum analyst target price is USD 0.85 while the minimum anlayst target price is USD 0.85.
NBY stock's Price/Earning ratio is 5.17.
Our analysis grades NBY stock's Price / Earning ratio at D-. This means that NBY stock's Price/Earning ratio is above 40% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this NBY may be fairly valued for its sector
The last closing price of NBY's stock was USD 0.60.
The most recent market capitalization for NBY is USD 3.18M.
Based on targets from 1 analysts, the average taret price for NBY is projected at USD 0.85 over the next 12 months.
This means that NBY's stock price may go up by +41.67% over the next 12 months.
We can't find any ETFs which contains NovaBay Pharmaceuticals Inc's stock.
As per our most recent records NovaBay Pharmaceuticals Inc has 24 Employees.
NovaBay Pharmaceuticals Inc's registered address is 2000 Powell Street, EmeryVille, CA, United States, 94608.
You can get more information about it from NovaBay Pharmaceuticals Inc's website at https://novabay.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NBY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
